Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Capital Employed (2019 - 2025)

UroGen Pharma (URGN) has disclosed Return on Capital Employed for 7 consecutive years, with 0.24% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed fell 13.0% year-over-year to 0.24%, compared with a TTM value of 0.24% through Dec 2025, down 13.0%, and an annual FY2025 reading of 0.18%, down 3.0% over the prior year.
  • Return on Capital Employed was 0.24% for Q4 2025 at UroGen Pharma, up from 0.42% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.1% in Q3 2022 and bottomed at 1.23% in Q1 2021.
  • Average Return on Capital Employed over 5 years is 0.32%, with a median of 0.2% recorded in 2022.
  • The sharpest move saw Return on Capital Employed tumbled -50bps in 2021, then soared 106bps in 2022.
  • Year by year, Return on Capital Employed stood at 0.24% in 2021, then rose by 4bps to 0.23% in 2022, then soared by 36bps to 0.15% in 2023, then increased by 21bps to 0.12% in 2024, then crashed by -110bps to 0.24% in 2025.
  • Business Quant data shows Return on Capital Employed for URGN at 0.24% in Q4 2025, 0.42% in Q3 2025, and 0.31% in Q2 2025.